Kisqali (ribociclib) vs Verzenio/Verzenios (abemaciclib)
Kisqali (ribociclib) vs Verzenio/Verzenios (abemaciclib)
Kisqali (ribociclib) and Verzenio (abemaciclib) are both CDK4/6 inhibitors used in the treatment of certain types of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, often in combination with an aromatase inhibitor or fulvestrant. While both medications work by interrupting the cell cycle and thus inhibiting cancer cell proliferation, they have different dosing schedules; Kisqali is typically taken once daily for 21 consecutive days followed by a 7-day break, whereas Verzenio is taken continuously without a break. The choice between Kisqali and Verzenio should be made in consultation with a healthcare provider, considering the individual's specific medical condition, treatment goals, potential side effects, and other medications being taken.
Difference between Kisqali and Verzenio/Verzenios
Metric | Kisqali (ribociclib) | Verzenio/Verzenios (abemaciclib) |
---|---|---|
Generic name | Ribociclib | Abemaciclib |
Indications | HR-positive, HER2-negative advanced or metastatic breast cancer | HR-positive, HER2-negative advanced or metastatic breast cancer |
Mechanism of action | CDK4/6 inhibitor | CDK4/6 inhibitor |
Brand names | Kisqali | Verzenio, Verzenios |
Administrative route | Oral | Oral |
Side effects | Neutropenia, nausea, infections, fatigue, diarrhea | Diarrhea, neutropenia, nausea, abdominal pain, infections |
Contraindications | Hypersensitivity to ribociclib; concomitant use with strong CYP3A inhibitors or inducers | Hypersensitivity to abemaciclib; concomitant use with strong CYP3A inhibitors or inducers |
Drug class | CDK4/6 inhibitor | CDK4/6 inhibitor |
Manufacturer | Novartis | Lilly |
Efficacy
Efficacy of Kisqali (Ribociclib) in Breast Cancer Treatment
Kisqali (ribociclib) is a targeted therapy drug that is used in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. Ribociclib specifically inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), which are proteins that play a role in cell division. By inhibiting these kinases, Kisqali helps to slow down the growth and spread of cancer cells. Clinical trials have shown that when combined with an aromatase inhibitor or fulvestrant, ribociclib significantly improves progression-free survival compared to the hormone therapy alone. This has led to its approval as a first-line treatment for postmenopausal women with this type of breast cancer, as well as for younger women who have received prior endocrine therapy.
Efficacy of Verzenio/Verzenios (Abemaciclib) in Breast Cancer Treatment
Verzenio, also known by its generic name abemaciclib, is another CDK4/6 inhibitor used in the treatment of HR+/HER2- advanced or metastatic breast cancer. Similar to ribociclib, abemaciclib works by disrupting the cell cycle, thus impeding the proliferation of cancer cells. The efficacy of Verzenio has been demonstrated in multiple clinical trials. When used in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women, abemaciclib has been shown to improve progression-free survival. Additionally, it is approved for use in combination with fulvestrant in women with disease progression following endocrine therapy, and as a monotherapy in patients who have previously undergone endocrine therapy and chemotherapy in the metastatic setting.
Both Kisqali and Verzenio have been groundbreaking in improving outcomes for patients with certain types of breast cancer. However, it is important to note that the efficacy of these drugs can vary based on individual patient factors, including the presence of certain genetic markers, previous treatments, and the specific characteristics of the cancer. Oncologists consider these factors when prescribing CDK4/6 inhibitors to ensure the best possible outcome for each patient.
It is also critical to recognize that while these medications have improved progression-free survival, side effects can occur, and long-term outcomes such as overall survival benefit are continually being evaluated through ongoing clinical trials and post-marketing surveillance. Patients on these therapies are closely monitored for adverse reactions and treatment efficacy, and the therapeutic regimen may be adjusted accordingly to optimize patient care and outcomes.
Regulatory Agency Approvals
Kisqali
Verzenio/Verzenios
Access Kisqali or Verzenio/Verzenios today
If Kisqali or Verzenio/Verzenios are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us